Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
InspireMD announces inducement grants under Nasdaq listing rule
InspireMD (NSPR) announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one new
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance,
Etsy Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Etsy, Inc. (Nasdaq: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that effective February 3,
BioCryst reports inducement grants under Nasdaq listing rule
Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees
Nuvini regais compliance with Nasdaq listing rule
Group received notice from the Listing Qualifications Department of the Nasdaq Stock Market on February 5, indicating that the ...
Nasdaq9d
Mainz Biomed Regains Compliance With Nasdaq Listing Rules
that it met the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). Mainz Biomed had previously met the minimum bid price requirement under Rule 5550(a)(2). With ...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 ...
Nuvini Regains Compliance with Nasdaq Listing Rule 5250(c)(2)
On February 4, 2025, the Company filed the required Form 6-K to report its unaudited condensed consolidated statements of profit or loss and statements of financial position as of and for the quarter, ...
Nasdaq12d
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant. Akebia Therapeutics, Inc. is a ...
Global Star Acquisition faces Nasdaq delisting over share shortfall
Global Star Acquisition Inc., a special purpose acquisition company with a market capitalization of $44.27 million, is confronting delisting from the Nasdaq Stock Market after failing to meet the ...